MEDIA

Video Feed

OncoSec at 2020 BIO CEO Panel

IAD Reel

Tumor Immunogenicity

IAD Robert Andtbacka, M.D.

TAVO Demonstration with Dr Algazi

3D MOA Animation video

Social Media

Twitter Feed

After being diagnosed with metastatic #melanoma, Sharon immediately had surgery to remove the #cancer. Unfortunately, this failed to stop her cancer from spreading. Today, she shares how she found hope through #clinicaltrial research. Listen to her story: https://oncosec.com/patients/

In Dr. Kristen Mueller’s latest article for @MelanomaReAlli, she explored the advantages of #intratumoral therapies and cytokine-based approaches, including our lead product candidate #TAVO™. Read the full article here: https://www.curemelanoma.org/blog/article/clinical-trials-to-watch-intralesional-therapies-for-melanoma

Our primary technology, #TAVOᵀᴹ, has the potential to become the first marketed therapeutic to address the unmet need of anti-PD-1 non-responders. TAVO is administered into the #tumor through electroporation (EP). Learn more about how TAVO and EP works: https://oncosec.com/tavo/

We recently sat down with Fran, Sharon and Julie to discuss their personal experiences using our #electroporation (EP) gene delivery system, which employs a series of momentary energy pulses. Learn about electroporation from a patient’s point of view: https://oncosec.com/patients/